News | August 11, 2021
Marksons Pharma PAT at Rs 62.6 cr. for Q1FY22
The company has tied up with OrbiMed as a financial partner for global reach
The company has tied up with OrbiMed as a financial partner for global reach
The profits were bolstered by the Boehringer Ingelheim MEK program income
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
The healthcare vertical is US-focused, has 35-plus clients and 24,000 employees across 34 locations in five countries
Nearly 6,000 patients have been treated with the drug since 2017
The drug is indicated for mild and transient episodes of heart block
The product can be used by any lab that conducts NGS testing, making precision medicine accessible to all cancer patients
Founded in 2019, the start-up develops digital therapeutics, a therapeutic intervention from the convergence of biology and information technology
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
Company working on COVID vaccine INO 4800
Subscribe To Our Newsletter & Stay Updated
